Evidence map›Paper›PMID 42368992›Full record

ArticleMediterranean journal of rheumatology2026

Serum Sclerostin Correlates with ACPA Positivity in Post-Menopausal Women with Rheumatoid Arthritis: Data from a Cross-Sectional Case-Control Study in Greece.

Michail I Krikelis, Dimitra Moschou, Konstantina Zoupidou, Evangelia Mole, Konstantinos Makris, Simeon Tournis, Sousana Gazi, Vassilios Nikolaou, Clio Mavragani, Efstathios Chronopoulos

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Mediterranean journal of rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Michail I KrikelisLaboratory for the Research of Musculoskeletal System "Th. Garofalidis", Medical School, National and Kapodistrian University of Athens, KAT General Hospital, Athens, Greece.
Dimitra MoschouRheumatologist, Larnaka, Cyprus.
Konstantina ZoupidouAttikon University Hospital, Rheumatology and Clinical Immunology Unit, 4th University Clinic of Internal Medicine, Athens, Greece.
Evangelia MoleRheumatology Department, KAT General hospital, Athens, Greece.
Konstantinos MakrisDepartment of Biochemistry, KAT General Hospital, Athens, Greece.
Simeon TournisLaboratory for the Research of Musculoskeletal System "Th. Garofalidis", Medical School, National and Kapodistrian University of Athens, KAT General Hospital, Athens, Greece.
Sousana GaziRheumatology Department, KAT General hospital, Athens, Greece.
Vassilios Nikolaou2nd University Clinic of Orthopaedic Surgery, Konstantopoulio General Hospital, Athens, Greece.
Clio MavraganiLaboratory of Experimental Physiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Efstathios ChronopoulosLaboratory for the Research of Musculoskeletal System "Th. Garofalidis", Medical School, National and Kapodistrian University of Athens, KAT General Hospital, Athens, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Rheumatoid arthritis (RA) is a chronic inflammatory disease marked by bone loss, partly due to impaired Wnt signalling. The role of sclerostin, an endogenous Wnt inhibitor, in RA remains unclear. Methods: This 9-month cross-sectional case-control study included post-menopausal women recruited at a tertiary hospital in Athens, Greece. Participants underwent clinical assessment, DXA, radiographs, and blood tests. The aim was to assess serum sclerostin levels and their associations in RA. Results: A total of 97 RA patients and 45 controls were included. Mean age was 67 ± 7 years; median RA duration was 8 years; 40% were seropositive; 65% received bDMARDs. Median sclerostin levels did not differ significantly between groups (p=0.645). In RA patients, sclerostin levels were positively associated with ACPA (p=0.043). Notably, 27% of RA patients had extremely high sclerostin levels versus 11% of controls (p=0.035). Within this subgroup, high sclerostin was inversely associated with sarcopenia (p=0.020). Discussion: Although overall sclerostin levels were similar between groups, higher levels in seropositive RA suggest a possible link with ACPA.

Indexed as

case-control studyGreeceosteoporosisrheumatoid arthritissarcopeniasclerostin

Identifiers

PMID42368992
PMCPMC13305845

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.